Use of GLP-1 or analogs in treatment of myocardial infarction

Abstract

This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.

I claim:  
     
         1 . A method of reducing mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives, and pharmaceutically-acceptable salts thereof, at a dose effective to normalize blood glucose.  
     
     
         2 . The method of  claim 1 , wherein the compound is administered intravenously.  
     
     
         3 . The method of  claim 1 , wherein the compound is administered subcutaneously.  
     
     
         4 . The method of claims  2  or  3 , wherein the administration is continuous.  
     
     
         5 . The method of  claim 4  wherein the rate of administration of the compound is between 0.25 and 6 pmol/kg/h.  
     
     
         6 . The method of  claim 5  wherein the rate of administration of the compound is between 0.6 and 2.4 pmol/kg/h.  
     
     
         7 . The method of claims  2  or  3  wherein the intravenous administration is intermittent.  
     
     
         8 . The method of  claim 2  wherein the compound is administered intravenously and also administered by another parenteral route.  
     
     
         9 . The method of  claim 8  wherein the other parenteral route is the subcutaneous route.  
     
     
         10 . The method of  claim 1  wherein the compound administered is GLP(7-36) amide, or a pharmaceutically-acceptable salt thereof.  
     
     
         11 . A method of reducing morbidity and mortality after myocardial infarction, comprising, administering a compound that exerts insulinotropic activity by interacting with the same receptor, or receptors, with which GLP-1, GLP-1 analogs, and GLP-1 derivatives interact in exerting their insulinotropic activity.  
     
     
         12 . A method of reducing morbidity and mortality after myocardial infarction, comprising, administering a compound that enhances insulin sensitivity by interacting with the same receptor, or receptors, with which GLP-1, GLP-1 analogs, and GLP-1 derivatives interact to enhance insulin sensitivity.